LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

High-Sensitivity Molecular Detection System Used in Cancer Screening

By LabMedica International staff writers
Posted on 04 Jan 2016
Print article
Image: Schematic diagram of the Liquid Biopsy platform LiqBiopSens concept (Photo courtesy of AWSensors).
Image: Schematic diagram of the Liquid Biopsy platform LiqBiopSens concept (Photo courtesy of AWSensors).
The current go-to method for reliable cancer diagnosis is tumor tissue biopsy, but this method is invasive, painful and expensive and it also only provides information of a single point in the evolution of the disease.

A technology has been developed for a high-sensitivity molecular detection system for use in cancer screening. It is based on a technique known as liquid biopsy: the analysis of small fluid samples, like blood or saliva, making it completely noninvasive.

The novel technology is fast, giving results within the hour and when combined with genomic analysis, it will be possible to obtain reliable early diagnoses and devise precision therapy approaches to cancer treatment. The new detection system will incorporate quartz microsensor technology patented by the Polytechnic University of Valencia (UPV; Spain) that allows real-time analysis, combined with technology that can reliably detect DNA mutations.

Technology developed at AWSensors (Valencia, Spain) and DestiNA Genomics, Ltd., Edinburgh. UK) will be used to advance this new system. By detecting both the DNA released by the tumor into the body and any cancer-associated mutations it undergoes, it will reliably detect the presence and evolution of the cancer, eliminating false positives.

The new system also has the advantage of being up to three times cheaper than other real-time methods, such as quantitative polymerase chain reaction (PCR), and can be carried out by non-specialists. The system called LiqBiopSens will therefore enable simple, inexpensive, noninvasive screening for early detection and periodic monitoring of tumors. The new system will be tested on the blood samples of colorectal cancer patients over the next three years. This cancer is the second cause of death in Europe and one of the most common, alongside breast, lung and prostate cancers.

Related Links:

Polytechnic University of Valencia 
AWSensors
DestiNA Genomics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more